|
Jon Moynihan, OBE (born 21 June 1948) is the former Executive Chairman of PA Consulting Group, the employee-owned firm of over 2,000 people, specialising in management and IT consulting, technology and innovation. 〔http://www.paconsulting.com/〕 Moynihan joined PA Consulting Group in 1992, as CEO and retired at the end of 2013. In 1997 The Wall Street Journal published an article giving an extensive review of PA’s turnaround, focusing on Moynihan’s role in that.〔The Wall Street Journal Europe (9 July 1997). Article by Shailagh Murray: ("British Consultancy Found Needy Client In Its Own Office - PA Group's Overhaul Offers Lesson in How to Survive Increasingly Tight Sector" )〕 In 1999, London’s ''The Sunday Times'' published an article discussing PA’s further success, highlighting Moynihan’s contribution to that.〔The Sunday Times (7 March 1999). Article by John Waples: ("Inspirational chief works wonders for PA Consulting" )〕 Jon continues to chair (Ipex Capital ), the demerged venture capital arm of PA, helping to bring leading-edge new technology capabilities to the market. Prior to the creation of IPEX Capital, Jon chaired all of PA's dozen or so ventures from inception through to disposition. Six of PA’s ventures have been sold to date, the most successful being Meridica Inc (maker of a novel drug inhaler), sold for $125m, and UbiNetics Ltd (3G mobile phone technology), sold for $132.5m.〔PA Consulting Group (12 November 2004). Press release: ("Pfizer completes acquisition of drug delivery technology venture from PA Consulting Group" )〕〔PA Consulting Group (23 May 2005). Press release: ("PA Consulting Group and 3i announce sale of UbiNetics' testing business" )〕〔PA Consulting Group (28 July 2005). Press release: ("PA Consulting Group and 3i announce sale of UbiNetics" )〕 The Ipex portfolio currently includes (Aegate ), an innovative leader in the field of drug authentication, formed to provide a global solution to the burgeoning problem of counterfeit drugs;〔Financial Times (20 November 2006). Article by Andrew Baxter: ("The war on drugs copycats" )〕 (Semblant ), developer of new PCB coating technology; and (PlaqueTec ), a company developing a novel coronary biomarker medical device. Another company (ProcServe ) continues to be a wholly owned business of PA Consulting Group, offering e-procurement solutions to both the Public and Private Sectors ==History== Moynihan was awarded an Open Scholarship in Mathematics at Balliol College Oxford (BA and MA in Psychology and Philosophy - PPP), with further education at North London Polytechnic - now part of the London Metropolitan University (MSc in Applied Statistics), and the MIT Sloan School of Management (MS in Business and Finance). After leaving Oxford University, Moynihan worked at Track Records, the management company for The Who and other rock bands. He then worked in India and Bangladesh, for War on Want and Save the Children. On his return to the UK, he worked at Roche Products Ltd, the UK arm of Hoffman-La Roche, as product manager for various anti-cancer, anti-epileptic, and anti-anxiety and insomnia drugs, including Valium and Mogadon. After taking his degree at MIT, Moynihan worked first at McKinsey & Company in Amsterdam (1977–79), then at Strategic Planning Associates (which became Mercer Management Consulting, and latterly Oliver Wyman) in Washington DC (1979–81), and then as a partner at First Manhattan Consulting Group in New York, from 1981 to 1992. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Jon Moynihan」の詳細全文を読む スポンサード リンク
|